Show simple item record

dc.contributor.authorRamos-Sevillano, Elisa 
dc.contributor.authorRodriguez-Sosa, Cinthya 
dc.contributor.authorCafini, Fabio
dc.contributor.authorGiménez, Maria-Jose
dc.contributor.authorNavarro, Ana 
dc.contributor.authorSevillano, David
dc.contributor.authorAlou, Luis
dc.contributor.authorGarcía, Ernesto
dc.contributor.authorAguilar, Lorenzo
dc.contributor.authorYuste, Jose Enrique
dc.identifier.citationPLoS One. 2012;7(9):e44135es_ES
dc.description.abstractBACKGROUND: Specific antibodies mediate humoral and cellular protection against invading pathogens such as Streptococcus pneumoniae by activating complement mediated immunity, promoting phagocytosis and stimulating bacterial clearance. The emergence of pneumococcal strains with high levels of antibiotic resistance is of great concern worldwide and a serious threat for public health. METHODOLOGY/PRINCIPAL FINDINGS: Flow cytometry was used to determine whether complement-mediated immunity against three antibiotic-resistant S. pneumoniae clinical isolates is enhanced in the presence of sub-inhibitory concentrations of cefditoren and ceftriaxone. The binding of acute phase proteins such as C-reactive protein and serum amyloid P component, and of complement component C1q, to pneumococci was enhanced in the presence of serum plus either of these antibiotics. Both antibiotics therefore trigger the activation of the classical complement pathway against S. pneumoniae. C3b deposition was also increased in the presence of specific anti-pneumococcal antibodies and sub-inhibitory concentrations of cefditoren and ceftriaxone confirming that the presence of these antibiotics enhances complement-mediated immunity to S. pneumoniae. CONCLUSIONS/SIGNIFICANCE: Using cefditoren and ceftriaxone to promote the binding of acute phase proteins and C1q to pneumococci, and to increase C3b deposition, when anti-pneumococcal antibodies are present, might help reduce the impact of antibiotic resistance in S. pneumoniae infections.es_ES
dc.description.sponsorshipThis work was supported by grants SAF2009-10824 from Dirección General de Investigación Científica y Técnica, MPY 1350/10 from ISCIII and an unrestricted educational grant from Tedec-Meiji Farma S. A. (Madrid, Spain). Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) is an initiative of the ISCIII. E.R-S. was supported by an FPU fellowship from Ministerio de Ciencia e Innovación and C.R-S was supported by a fellowship from MAEC-AECID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptes_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.subject.meshAcute-Phase Proteins es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAnti-Bacterial Agents es_ES
dc.subject.meshAntibodies es_ES
dc.subject.meshCeftriaxone es_ES
dc.subject.meshCephalosporins es_ES
dc.subject.meshComplement Activation es_ES
dc.subject.meshComplement C1q es_ES
dc.subject.meshComplement C3c es_ES
dc.subject.meshDrug Resistance, Microbial es_ES
dc.subject.meshEgtazic Acid es_ES
dc.subject.meshFlow Cytometry es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmune System es_ES
dc.subject.meshMice es_ES
dc.subject.meshPhagocytosis es_ES
dc.subject.meshStreptococcus pneumoniae es_ES
dc.subject.meshbeta-Lactams es_ES
dc.titleCefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strainses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderTedec-Meiji Farma
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional